Actively Recruiting
Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas
Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2024-09-05
150
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this study is to explore the associations between T cell activation and the occurrence of hemophagocytic lymphohistiocytosis (HLH) in patients with newly diagnosed lymphomas. The specific aims are: Prediction of Lymphoma-Associated HLH (LA-HLH): Compare flow cytometric T cell activation markers with the H-score to predict LA-HLH. Identification of new markers for predicting HLH in patients with aggressive lymphoma. Description of the incidence rate of LA-HLH. Assessment of the outcomes of LA-HLH identified by flow cytometric analysis or the H-score. This prospective, single-center observational study will include 150 patients newly diagnosed with aggressive lymphoma within one year. Peripheral blood samples will be taken at diagnosis alongside routine blood chemistry tests for flow cytometric analysis of the T-lymphocyte activation profile. Data on disease characteristics will be collected to calculate the H-score, HLH-2004 score, and OHI score for diagnosing HLH. The flow cytometry results will be compared with these scores to evaluate their effectiveness in diagnosing LA-HLH.
CONDITIONS
Official Title
Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Diagnosis at onset of aggressive lymphoma including Hodgkin lymphoma
- Diagnosis of transformed B cell lymphomas
- Diagnosis of diffuse large B-cell lymphomas including various subtypes
- Diagnosis of Burkitt lymphoma
- Diagnosis of KSHV/HHV8 associated lymphomas
- Diagnosis of lymphomas associated with immunodeficiency or immune dysregulation
- Diagnosis of mature T-cell-derived lymphomas including various subtypes
- Informed consent to use biological materials for the study
You will not qualify if you...
- Diagnosis of indolent non-Hodgkin's lymphoma or other lymphoma diagnoses not listed in inclusion
- Prolonged steroid therapy longer than 15 days or high steroid doses exceeding 1 mg/kg
- Age 18 years or younger
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Stefan Hohaus
Rome, Lazio, Italy, 00168
Actively Recruiting
Research Team
S
Stefan Hohaus, MD
CONTACT
F
Flaminia Bellisario, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here